Featuring Four Keynote Presentations, Four Pre-Conference Summits, Six Therapeutics Conference Topics, Three Post-Conference Workshops and Over
One Hundred and Seventy Exhibitors
WESTBOROUGH, Mass., Aug. 4 /PRNewswire/ -- Today IBC Life Sciences kicks off the 13th Annual Drug Discovery & Development of Innovative Therapeutics (DDT) World Congress in Boston, Massachusetts. 3,000 pharmaceutical, biotechnology, government and academic researchers, executives and technology providers to attend.
The keynote speakers include Elliott Sigal, M.D., Ph.D, from Bristol-Myers Squibb Company and William C. Bertrand, Jr., J.D. Executive Vice President, from MedImmune, Inc. Keynote panel discussions will approach "controversial" topics such as the FDA position on biomarkers and the impact of the 2008 elections on the future of the pharmaceutical/healthcare industry.
The conference sessions will cover six therapeutics areas and four additional drug discovery and development areas: Therapeutic Advances in: Cancer, Cardio-Metabolic, Neurodegeneration, Anti-infectives, Orphan Diseases, Inflammation; Transforming Technologies; Translational Medicine; Next Generation Therapeutics; and R&D Strategies.
The exhibit hall is open on Tuesday, August 5 (10:00 am -7:30 pm) and Wednesday, Aug 6 (10:30 am -5:00 pm). Over 170 drug discovery and development companies will be exhibiting, including 34 new exhibitors and 47 new product launches. Key sponsors of the event include Bend Research Inc., BMG LABTECH, CambridgeSoft Corporation, ChemAxon, ForteBio, Merck, and Tata Consultancy Services.
For additional details visit http://www.drugdisc.com.
About IBC Life Sciences
IBC Life Sciences is the worldwide leader in scientific, technological
and business conferences and courses for the life science industry. To
develop its programs, IBC actively researches the advancements
|SOURCE IBC Life Sciences|
Copyright©2008 PR Newswire.
All rights reserved